Atirmociclib
As of the edition of 20 October 2026, Atirmociclib is a small molecule: in active development; acts on CDK4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2029
- Kind
- Small molecule
- Registered trials
- 16, 0 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Digestive system; Lungs and airways; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Atirmociclib.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CDK4 | Cyclin-dependent kinase 4 | P11802 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 9 | 5 | 4 | 0 |
| Phase 2 | 6 | 1 | 5 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 16 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Roche | Lead sponsor of trials | 2018 to now |
| Pfizer | Lead sponsor of trials | 2020 to now |
| Relay Therapeutics | Lead sponsor of trials | 2021 to now |
| Olema Pharmaceuticals | Lead sponsor of trials | 2022 to now |
| OnKure | Lead sponsor of trials | 2024 to now |
| AstraZeneca | Lead sponsor of trials | 2026 to now |